Abstract

Background: Although the possible interference of digoxin-like immunoreactive substances (DLIS) on the Architect ® iDigoxin chemiluminiscent microparticle immunoassay (CMIA) has been emphasized by the manufacturer, a specific study about this subject has still not been carried out.
Methods: Apparent serum digoxin concentrations were determined using the Architect® iDigoxin CMIA from Abbott Laboratories in digoxin-free pregnant women (n = 50), and patients with liver disease (n = 50), renal insufficiency (n = 50), kidney (n = 25) or liver (n = 25) transplant, and critical illness (n = 50).
Results: In all of the patients included in this study, apparent serum digoxin concentrations were lower than the
correspondent quantification limit (< 0.30 μg/L).
Conclusions: The Architect® iDigoxin CMIA assay would be relatively free from endogenous DLIS positive interferences.

DOI: 10.7754/Clin.Lab.2012.120325